There is no excerpt because this is a protected post.
Read more
All posts by CAC2
Guest Blog–National Cancer Institute Launches Molecular Characterization Initiative for Childhood Cancer Research
The National Cancer Institute’s new Molecular Characterization Initiative (MCI) fosters data sharing in childhood cancer research. The program currently offers comprehensive molecular characterization of tumors to children, adolescents, and young adults (AYAs) with newly diagnosed central nervous system tumors receiving care at hospitals affiliated with the Children’s Oncology Group. The DNA and RNA in participants’ tumors are analyzed through this voluntary, free program. Participants’ tumor and blood samples are analyzed in an accredited lab, with results shared with families and doctors within 21 days. This detailed information about the cancer can be used to make a more precise diagnosis, […]
Read more
CAC2 Childhood Cancer Community News Digest (March 14-20)
Assorted News from Last Week:
Read more
CAC2 Childhood Cancer Community News Digest (March 7-13)
Assorted News from Last Week: Congress approved the fiscal year 2022 omnibus spending package on March 11. It included great news for the childhood cancer community: the STAR Act will receive $30M and the Childhood Cancer Data Initiative will receive $50M. Pediatric cancer mortality and survival has only improved over the past 40 years in the United States (US) but disparities remain. However, there are often various factors that play a role including age, race/ethnicity, cancer site, and economic status, which can change the outcome or treatments of individuals. In one of the most complicated evacuations likely ever managed from […]
Read more
Community News–Federal Appropriations 2022 Passes
Congress approved the fiscal year 2022 omnibus spending package on March 11. It included great news for the childhood cancer community: the STAR Act will receive $30M and the Childhood Cancer Data Initiative will receive $50M. There were several other specifics in the budget important for our community: NIH/HHS Funding The STAR Act received $30M and CCDI received $50M for FY22 – full funding for both programs! NIH received $45B for FY22, an increase of $2.25B over FY21. NCI received $6.9B for FY22, an increase of $353M over FY21. This also includes $194M for the Cancer Moonshot. The omnibus provided $1B […]
Read more
CAC2 Childhood Cancer Community News Digest (February 28-March 6)
Assorted news from last week: Steven E. Lipshultz, MD, is senior author on a new study that shows healthier hearts in long-term childhood cancer survivors treated with a new drug, dexrazoxane, to protect their hearts from heart-damaging chemotherapy — even in those treated nearly 20 years ago. Survivors of childhood cancer who became pregnant in adulthood are as likely to have healthy babies as those without a history of cancer, according to a new study. Their children also didn’t have higher risks of birth defects or other health problems at birth. However, the study does suggest that these women face [...] Read more
CAC2 Childhood Cancer Community News Digest (February 21-27)
Assorted news from last week: The story of Moonshot4Kids meets the White House Moonshot: CAC2 Member Janet Demeter (Jack’s Angels) encourages medical research investment into cures for children with cancer at the 2022 Cancer Moonshot announcement event. CAC2 Member, the National Brain Tumor Society (NBTS) launched a new research initiative, the DNA Damage Response Consortium, in partnership with Yale Cancer Center. The consortium will bring together a diverse team of renowned adult and pediatric researchers to rapidly advance a new class of promising potential treatments that can target a brain tumor’s DNA damage response network. More than 60% of patients with […]
Read more
Member Blog–If No One Knows, No One Cares: An Urgent Message for President Biden
By CAC2 Member Janet Demeter, Jack’s Angels “This is the wake up call of #Moonshot4Kids: medical research investment into cures for children is one area where our priorities as Americans are completely upside-down.”–Janet Demeter This is the story of Moonshot4Kids meets the White House Moonshot! I visited the White House on Feb. 2, 2022 to witness President Biden’s announcement to reignite the Cancer Moonshot. I never expected an invitation to this event. At the end of last year, I had been involved in a White House OSTP roundtable of stakeholders in the childhood cancer community at the end of last […]
Read more
CAC2 Childhood Cancer Community News Digest (February 14-20)
Assorted news from last week: Study finds no link between Body Mass Index and thyroid cancer in teens with nodules. When acute myeloid leukemia (AML) relapses, it is more difficult to treat and outcomes are dismal. Scientists at St. Jude Children’s Research Hospital have discovered a mutation in pediatric AML that physicians can use to identify high-risk patients and better guide treatment. An elevated level of urinary 3-methoxytyramine (3MT) is tied to poor prognosis in pediatric neuroblastoma, according to research published in JCO Precision Oncology. Researchers also found that elevated 3MT was associated with 8 differentially expressed genes, providing a gene […]
Read more
CAC2 Childhood Cancer Community News Digest (February 7-13)
Assorted news from last week: Dr. Brigitte Widemann appointed as the Special Advisor to NCI Director Ned Sharpless for childhood cancer. When Jace Ward joined a clinical trial for a novel therapy for DIPG, he had been fighting a deadly brainstem tumor for more than a year. He told his Doctor at Stanford, Michelle Monje, “I know that I’m going to die, and I know this therapy will one day be the thing that cures other kids. Figure it out with me… I don’t want it to be a 5-year-old who has to go first.” This is his story and the […]
Read more